- Home
- ONDS vs ENTX Comparison
ONDS vs ENTX Comparison
Compare ONDS & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONDS
- ENTX
- Stock Information
- Founded
- ONDS 2014
- ENTX 2010
- Country
- ONDS United States
- ENTX Israel
- Employees
- ONDS N/A
- ENTX N/A
- Industry
- ONDS Telecommunications Equipment
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ONDS Telecommunications
- ENTX Health Care
- Exchange
- ONDS Nasdaq
- ENTX Nasdaq
- Market Cap
- ONDS 102.0M
- ENTX 104.0M
- IPO Year
- ONDS N/A
- ENTX 2018
- Fundamental
- Price
- ONDS $1.22
- ENTX $1.85
- Analyst Decision
- ONDS Strong Buy
- ENTX Strong Buy
- Analyst Count
- ONDS 2
- ENTX 1
- Target Price
- ONDS $3.25
- ENTX $10.00
- AVG Volume (30 Days)
- ONDS 7.6M
- ENTX 39.1K
- Earning Date
- ONDS 05-15-2025
- ENTX 05-09-2025
- Dividend Yield
- ONDS N/A
- ENTX N/A
- EPS Growth
- ONDS N/A
- ENTX N/A
- EPS
- ONDS N/A
- ENTX N/A
- Revenue
- ONDS $10,815,867.00
- ENTX $223,000.00
- Revenue This Year
- ONDS $256.61
- ENTX N/A
- Revenue Next Year
- ONDS $104.92
- ENTX N/A
- P/E Ratio
- ONDS N/A
- ENTX N/A
- Revenue Growth
- ONDS N/A
- ENTX N/A
- 52 Week Low
- ONDS $0.54
- ENTX $1.41
- 52 Week High
- ONDS $3.40
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- ONDS 72.31
- ENTX 39.76
- Support Level
- ONDS $0.83
- ENTX $1.69
- Resistance Level
- ONDS $1.15
- ENTX $2.08
- Average True Range (ATR)
- ONDS 0.11
- ENTX 0.13
- MACD
- ONDS 0.04
- ENTX -0.03
- Stochastic Oscillator
- ONDS 97.87
- ENTX 28.18
About ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.